Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer